Symmetry Partners LLC Has $634,000 Holdings in Stryker Corporation (NYSE:SYK)

Symmetry Partners LLC reduced its stake in Stryker Corporation (NYSE:SYK) by 2.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,703 shares of the medical technology company’s stock after selling 34 shares during the period. Symmetry Partners LLC’s holdings in Stryker were worth $634,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Kohmann Bosshard Financial Services LLC bought a new position in Stryker during the 4th quarter worth $25,000. Capital A Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter worth about $26,000. Rakuten Securities Inc. lifted its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the period. City Holding Co. increased its position in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares during the period. Finally, BankPlus Trust Department bought a new position in Stryker during the 4th quarter worth approximately $33,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of Stryker stock opened at $379.03 on Tuesday. The business’s fifty day simple moving average is $375.47 and its 200 day simple moving average is $375.11. The firm has a market capitalization of $144.67 billion, a P/E ratio of 51.22, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company posted $2.50 earnings per share. As a group, analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. Stryker’s payout ratio is 45.41%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SYK. Evercore ISI reduced their price objective on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Monday, May 5th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Finally, Roth Mkm lifted their target price on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.